Related Experiment Video

Updated: Aug 17, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Therapeutic targeting of receptor tyrosine kinases in lung cancer

Nicholas W Choong1, Patrick C Ma, Ravi Salgia

  • 1University of Chicago Medical Center, Pritzker School of Medicine, MC 2115, 5841, S. Maryland Avenue, Chicago, IL 60615, USA.

Expert Opinion on Therapeutic Targets
|June 14, 2005
PubMed

Insights

Novel therapeutics targeting receptor tyrosine kinases show promise for improving lung cancer treatment outcomes. Understanding these key drivers offers new hope for patients with this challenging disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Translational Medicine

Background:

  • Lung cancer remains a significant health challenge with limited survival rates despite conventional treatments.
  • Current therapeutic strategies including chemotherapy, radiation, and surgery offer suboptimal outcomes.
  • Receptor tyrosine kinases (RTKs) are increasingly recognized for their role in lung cancer development and progression.

Purpose of the Study:

  • To review the biological mechanisms of major RTKs implicated in lung cancer.
  • To detail novel therapeutic inhibitory strategies targeting these RTKs in preclinical and clinical development.
  • To highlight the potential impact of RTK-targeted therapies on lung cancer treatment.

Main Methods:

  • Literature review of basic biological studies on RTKs in lung cancer.
  • Summary of the roles of epidermal growth factor receptor (EGFR), Her2/neu, MET, vascular endothelial growth factor (VEGF), and KIT.
  • Compilation of ongoing preclinical and clinical studies on novel RTK inhibitors.

Main Results:

  • Detailed description of the biology of key RTKs (EGFR, Her2/neu, MET, VEGF, KIT) in lung cancer.
  • Identification of various novel therapeutic strategies targeting these RTKs.
  • Overview of the current status of these targeted therapies in preclinical and clinical investigations.

Conclusions:

  • Understanding the biology of RTKs is crucial for advancing lung cancer treatment.
  • Targeted inhibition of specific RTKs represents a promising avenue for novel lung cancer therapeutics.
  • RTK-targeted therapies hold the potential to significantly improve outcomes for lung cancer patients.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...